A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer

Inclusion Criteria

• •18-70 years
• •Obtain an informed consent form voluntarily signed by the patient themselves
• •patients with Unresectable Pancreatic Cancer confirmed by Histopathology
• •Patients who either: 1) have received standard first-line treatments, proven ineffective or causing intolerable adverse effects; or 2) have not received the standard first-line treatments and voluntarily opt for Autologous Drug-Loaded Neutrophils (NeuMed)-based therapy
• •EOCG score ≤ 2 and expected survival time ≥ 3 months
• •Liver, kidney and bone marrow functions are basically normal